Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Trial Profile

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs CERC 501 (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 20 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 13 Sep 2016 According to Cerecor media release, top-line data is expected in December 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top